Primary plasma cell leukemia in the era of new drugs: Has something changed?

Critical Reviews in Oncology/Hematology

Volumn 82, Issue 2, 2012, Pages 141-149

  Musto, Pellegrino ^a   Pagano, Livio ^b   Petrucci, Maria Teresa ^c   Morabito, Fortunato ^d   Caravita, Tommaso ^e   Di Raimondo, Francesco ^f   Baldini, Luca ^g   Tosi, Patrizia ^h   Bringhen, Sara ⁱ   Offidani, Massimo ^k   Omede', Paola ⁱ   Neri, Antonino ^g   D'Auria, Fiorella ^a   Bochicchio, Giovanni Battista ^a   Cavo, Michele ^j   Boccadoro, Mario ⁱ   Palumbo, Antonio ⁱ  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Azienda Ospedaliera di Cosenza   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h Ospedale Infermi di Rimini   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j UNIVERSITY OF BOLOGNA   (Italy)

^k OSPEDALI RIUNITI   (Italy)

more..

Author keywords

Bortezomib; Lenalidomide; Myeloma; Plasma cell leukemia; Stem cell transplantation; Thalidomide

Indexed keywords

BORTEZOMIB; CARMUSTINE; CD20 ANTIGEN; CD23 ANTIGEN; CD27 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; GRAFT VERSUS LEUKEMIA EFFECT; HEPATITIS B; HUMAN; INFECTION; LEUKEMIA REMISSION; LOW DRUG DOSE; MAINTENANCE THERAPY; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; PNEUMONIA; PRIMARY PLASMA CELL LEUKEMIA; PROGRESSION FREE SURVIVAL; REVIEW; SECONDARY PLASMA CELL LEUKEMIA; SIDE EFFECT; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, PLASMA CELL;

EID: 84859435524     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.04.005     Document Type: Review

References (79)

1. International Myeloma Working Group Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003, 121:749-757.
2. McKenna R.W., Kyle R.A., Kuehl W.M., Grogan T.M., Harris N.L., Coupland R.W. Plasma cell neoplasms. WHO classification of tumors of hematopoietic and lymphoid tissues 2008, 200-213. Published by IARC, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
3. Han X., Kilfoy B., Zheng T., et al. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control 2008, 19:841-858.
4. Sant M., Allemani C., Tereanu C., et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010, 116:3724-3734.
5. Blade J., Kyle R.A. Non secretory myeloma, immunoglobulin D myeloma and plasma cell leukemia. Hematol Oncol Clin North Am 1999, 13:1259-1272.
6. Garcia-Sanz R., Orfao A., Gonzalez M., et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999, 93:1032-1037.
7. Albarracin F., Fonseca R. Plasma cell leukemia. Blood Rev 2011, 25(3):107-112.
8. Ramsingh G., Mehan P., Luo J., Vij R., Morgensztern D. Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer 2009, 115:5734-5739.
9. Jimenez-Zepeda V.H., Dominguez-Martinez V.J. Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. Int J Hematol 2009, 89:259-268.
10. Sher T., Miller K.C., Deeb G., Lee K., Chanan-Khan A. Plasma cell leukaemia and other aggressive plasma cell malignancies. Br J Haematol 2010, 150:418-427.
11. Gertz M.A., Buadi F.K. Plasma cell leukemia. Haematologica 2010, 95(May 5):705-707.
12. Liedtke M., Medeiros B.C. Plasma cell leukemia: concepts and management. Exp Rev Hematol 2010, 3:543-549.
13. Cha C.H., Park C.J., Huh J.R., Chi H.S., Suh C.W., Kang Y.K. Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia. Acta Haematol 2007, 118:178-182.
14. Avet-Loiseau H., Daviet A., Brigaudeau C., et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique. Blood 2001, 97:822-825.
15. Chang H., Sloan S., Li D., Patterson B. Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization. Cancer Genet Cytogenet 2005, 156:150-153.
16. Tiedemann R.E., Gonzalez-Paz N., Kyle R.A., et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008, 22:1044-1052.
17. Kraj M., Kopeć-Szlezak J., Pogłód R., Kruk B. Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia. Leuk Res 2011, 35(2):169-176.
18. Walters M., Olteanu H., Van Tuinen P., Kroft S.H. CD23 expression in plasma cell myeloma is specific for abnormalities of chromosome 11, and is associated with primary plasma cell leukaemia in this cytogenetic sub-group. Br J Haematol 2010, 149:292-293.
19. Buda G., Carulli G., Orciuolo E., et al. CD23 expression in plasma cell leukaemia. Br J Haematol 2010, 150:724-725.
20. Katodritou E., Verrou E., Gastari V., Hadjiaggelidou C., Terpos E., Zervas K. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?. Leuk Res 2008, 32:1153-1156.
21. Chang H., Qi X., Yeung J., Reece D., Xu W., Patterson B. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res 2009, 33:259-262.
22. Fonseca R., Bergsagel P.L., Drach J., et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009, 23:2210-2221.
23. Chiecchio L., Dagrada G.P., White H.E., et al. Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer 2009, 48:624-636.
24. Noel P., Kyle R.A. Plasma cell leukaemia: an evaluation of response to therapy. Am J Med 1987, 83:1062-1067.
25. Bernasconi C., Castelli G., Pagnucco G., Brusamolino E. Plasma cell leukemia: a report on 15 patients. Eur J Haematol 1989, 51(Suppl.):76-83.
26. Dimopoulos M.A., Palumbo A., Delasalle K.B., Alexanian R. Primary plasma cell leukemia. Br J Haematol 1994, 88:754-760.
27. Costello R., Sainty D., Bouabdallah R., et al. Primary plasma cell leukaemia: a report of 18 cases. Leuk Res 2001, 25:103-107.
28. Vela-Ojeda J., Garcia-Ruiz Esparza M.A., Rosas-Cabral A., et al. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol 2002, 81:362-367.
29. Jimenez-Zepeda V.H., Dominguez V.J. Plasma cell leukemia: a rare condition. Ann Hematol 2006, 85:263-267.
30. Colović M., Janković G., Suvajdzić N., Milić N., Dordević V., Janković S. Thirty patients with primary plasma cell leukemia: a single center experience. Med Oncol 2008, 25:154-160.
31. Peijing Q., Yan X., Yafei W., et al. A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China. Acta Haematol 2009, 121:47-51.
32. Pagano L, Valentini CG, De Stefano V, et al. Primary plasma cell leukemia: a retrospective multi center study of 73 patients. Ann Oncol. 2011 Jan 20. [Epub ahead of print].
33. Yeh K.H., Lin M.T., Tang J.L., Yang C.H., Tsay W., Chen Y.C. Long-term disease-free survival after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by third-complementarity-determining region-specific probes. Br J Haematol 1995, 89:914-916.
34. Sajeva M.R., Greco M.M., Cascavilla N., et al. Effective autologous peripheral blood stem cell transplantation in plasma cell leukemia followed by T-large granular lymphocyte expansion: a case report. Bone Marrow Transplant 1996, 18:225-227.
35. Hovenga S., de Wolf J.T., Klip H., Vellenga E. Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature. Bone Marrow Transplant 1997, 20:901-904.
36. Sica S., Chiusolo P., Salutari P., et al. Long-lasting complete remission in plasma cell leukemia after aggressive chemotherapy and CD34-selected autologous peripheral blood progenitor cell transplant: molecular follow-up of minimal residual disease. Bone Marrow Transplant 1998, 22:823-825.
37. Panizo C., Rifon J., Rodriguez-Wilhelmi P., Cuesta B., Rocha E. Long-term survival in primary plasma cell leukemia after therapy with VAD, autologous blood stem cell transplantation and interferon-alpha. Acta Haematol 1999, 101:193-196.
38. Abe M., Yokoyama H., Tohmiya Y., et al. Plasma cell leukemia maintaining complete remission by syngeneic stem cell transplantation combined with low-dose thalidomide maintenance therapy. Intern Med 2009, 48:1833-1835.
39. Nonami A., Miyamoto T., Kuroiwa M., et al. Successful treatment of primary plasma cell leukaemia by allogeneic stem cell transplantation from haploidentical sibling. Jpn J Clin Oncol 2007, 37:969-972.
40. Johnson M.R., Del Carpio-Jayo D., Lin P., et al. Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation. Ann Diagn Pathol 2006, 10:263-268.
41. Masuda M., Inoue Y., Tanosaki R., Kanzaki S., Ogawa K. Development of solitary plasmacytoma in the internal auditory canal and inner ear after allogeneic hematopoietic stem cell transplantation for plasma cell leukemia. Jpn J Clin Oncol 2007, 37:701-703.
42. Saccaro S., Fonseca R., Veillon D.M., et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 2005, 78:288-294.
43. Mahindra A., Vesole D., Kalycio M.E., et al. Autologous hematopoietic stem cell transplantation (HCT) is a safe and effective treatment for primary plasma cell leukemia: the CIBMTR experience. Blood 2009, 114:532. [abstract].
44. Drake M.B., Iacobelli S., van Biezen A., et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica 2010, 95:804-809.
45. Oka S., Yokote T., Akioka T., et al. Successful treatment of multi-agent chemotherapy with rituximab for IgM plasma cell leukemia. Leuk Res 2006, 30:1581-1583.
46. Gemmel C., Cremer F.W., Weis M., et al. Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation. Ann Hematol 2002, 81:119-123.
47. Korte W., Jost C., Cogliatti S., Hess U., Cerny T. Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy. Ann Oncol 1999, 10:1249-1250.
48. Musto P., Carella A.M., Greco M.M., et al. Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. Br J Haematol 2003, 123:746-747.
49. Bauduer F. Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma. Br J Haematol 2002, 117(June 4):996-997.
50. Tsiara S., Chaidos A., Kapsali H., Tzouvara E., Bourantas K.L. Thalidomide administration for the treatment of resistant plasma cell leukemia. Acta Haematol 2003, 109:153-155.
51. Brück P., Mousset S., Bühme A., Hoelzer D., Atta J. Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment. Int J Hematol 2007, 86:66-68.
52. Johnston R.E., Abdalla S.H. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma 2002, 43:351-354.
53. Murthy V., Mwirigi A., Ward S., Rassam S.M.B. Rapid and excellent response to hyper-CVAD, particularly with thalidomide, in plasma cell leukaemia and long term remissions following allogeneic stem cell transplantation. Blood 2009, 114:4263. [abstract].
54. Petrucci M.T., Martini V., Levi A., et al. Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk Lymphoma 2007, 48:180-182.
55. Ballanti S., Mastrodicasa E., Bolli N., et al. Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia. Nat Clin Pract Oncol 2007, 4:722-725.
56. Pretz J., Medeiros B.C. Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: no recurrence with subsequent lenalidomide therapy. Am J Hematol 2009, 84:698-699.
57. Benson D.M., Smith M.K. Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leuk Lymphoma 2007, 48:1423-1425.
58. Musto P., Pietrantuono G., Guariglia R., et al. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res 2008, 32:1637-1638.
59. Guglielmelli T., Merlini R., Giugliano E., Saglio G. Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia. J Oncol 2009, 2009:867380. epub.
60. Olivieri A., Attolico I., Cimminiello M., Discepoli G., Cifarelli R.A. Lenalidomide can induce graft versus leukemia effect in primary plasma cell leukemia: a case report. Leuk Res 2009, 33:e191-e193.
61. Musto P., D'Auria F., Petrucci M.T., et al. Lenalidomide plus low dose dexamethasone as first line therapy in patients with primary plasma cell leukemia: planned interim analysis of a pilot study from the GIMEMA/Italian Myeloma Network. Haematologica 2010, 95(Suppl. 2):394. [abstract].
62. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
63. Esparis-Ogando A., Alegre A., Aguado B., et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005, 114:665-667.
64. Ataergin S., Arpaci F., Kaya A., Kaya T., Gunhan O. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia. Am J Hematol 2006, 81:986-987.
65. Ali R., Beksac M., Ozkalemkas F., et al. Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia. Leuk Lymphoma 2007, 48:1426-1428.
66. Telek B., Méhes L., Batár P., Kiss A., Udvardy M. Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation. Orv Hetil 2008, 149:1957-1959.
67. Kim S.J., Kim J., Cho Y., Seo B.K., Kim B.S. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia. Jpn J Clin Oncol 2007, 37:382-384.
68. Bernardeschi P., Pirrotta M.T., Montenora I., et al. Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record. Leuk Res 2010, 34:e104-e105.
69. Grassinger J., Sudhoff T., Andreesen R., Hennemann B. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol 2006, 85:132-133.
70. Krüger W.H., Kiefer T., Schüler F., Lotze C., Busemann C., Dölken G. Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation. Onkologie 2007, 30:193-195.
71. Finnegan D.P., Kettle P., Drake M., et al. Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma 2006, 47:1670-1673.
72. Capalbo S., Chiefa A., Delia M., Diomede D., Liso V. Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement. Acta Oncol 2007, 46:262-264.
73. Libby E., Candelaria-Quintana D., Moualla H., Abdul-Jaleel M., Rabinowitz I. Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen. Am J Hematol 2010, 85:733-734.
74. Chan S.M., George T., Cherry A.M., Medeiros B.C. Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report. Cases J 2009, 2:121.
75. Al-Nawakil C., Tamburini J., Bardet V., et al. Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leuk Lymphoma 2008, 49:2012-2014.
76. Musto P., Rossini F., Gay F., et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007, 109:2285-2290.
77. Musto P., Valentini C., D'Auria F., et al. Bortezomib-containing combinations as front-line therapy in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma and Acute Leukemia Working Parties. Haematologica 2010, 95(Suppl. 2):395. [abstract].
78. Mele G., Pinna S., Melpignano A., Quarta G. Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens. Clin Ther 2010, 32:915-919.
79. Jaskiewicz A.D., Herrington J.D., Wong L. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy 2005, 25:1820-1825.